Everybody is entitled to formulate their own opinion, its our peragative . Here is mine ! First let me preface !Anybody who takes the time to blog has some agenda. Some are more overt than others. Mine is to be objective as possible,looking at the facts. It seems the prevailing sentiment has become overtly negative and unjustly directed at the CEO. So contrary to public opinion I will be the contrarian !
I"ll begin by disclosing that I have a large long position and was an original DMI sharholder subsequent to receiving ampio shares. Its important for me to reflect historically on DMI biosciences and the inception of Ampio to the present. Knowing the history provides some insite and comparison to the truely acknowelge the unparreled accomplishments. Mike Macaluso is a savior. He purchased a fledgling dysfunctional biotech company, for 18yrs prior to his arrival had the dubious distinction of producing great science and 103 patents but lacking the leadership to monetize their assets. The company had no direction and was essentially bankrupt. Mike purchased the company in 2008 and convinced Dr. Bar-or to focus his Einstein billiance on the most relevant and commercially viable drugs. Even more remarkable was his timing. He purchased the company in the midst of the finacial meltdown. Conventional Banking and Equity Banking were non-existant ! His resourcefulness ,and perserverance provided him an opportunity to capitilize on a distressed asset that most would not contemplate under such adverse conditions. With in one year Mike advanced and enhanced the valuation of DMI .DMI went from the pink sheets where 90% of companies languish in oblivion,to the prestige of the nasdaq coinsiding with the subsequent name change to Ampio. This same year he achieved an unprecedented listing on the russell indexes. Here we are two yrs. later, 3 pivitol trials with guidence from the FDA. ,fully financed and fully enrolled .
What is all the fuss ? !!
Sentiment: Strong Buy
...for such an abject failure to properly get the story across to institutions. Hence you have great execution by AMPE with it's business plan but a stock price that reflects none of it.
You mean "Big Mac!" This is a great flea market. AMPE WILL RISE VERY QUICKLY,
Sentiment: Strong Buy
The only thing that has changed with AMPE is that they are getting closer to big valuation events.
It's a frustrating time but use that to your advantage to buy more. You won't regret it. Those selling today will be kicking themselves for years to come. Don't be one of those. Be a winner, get rich by buying more.
Big Mike is on top of everything and he has your back. Just be patient. We have the goods and shareholder rewards are coming soon.
There is a strategy that will work that may allow getting along without a big name banker.
Sentiment: Strong Buy
Kudos for writing this th3...the pressure gets to us sooner than later. It's all good, glad to have you back!
Sentiment: Strong Buy
We were about to do a $100M secondary (through Prudential and Kidder Peabody) when the first Gulf War broke out. Ended up selling it - in two different pieces. Did ok (pretty well by my low standards), but I had competitors that had better management (translation: they were better than me - smarter, more experienced, and with a better board).
Maybe this is the best thing to do... A series of rants based on personal frustration is often not worth reading after all. Sorry I let it get the better of me... and threw my barbs at what appeared to be the easiest of targets. ... with head bowed... I am faithfully yours, th3k33p3r24.
Point taken. These guys probably eat, sleep, and dream about the FDA. But it just seems to me in an investor presentation you should be emphasizing the value proposition not the FDA process. There should be a way to do that without offending the FDA. If not we shouldn't be blaming management for ineffectual promotion. I must add that I think Cavalli's point about low share prices and potential offers from BP has merit.
ed007... you are probably right. My apologies. And for all I know, Mr. Giles may be one of the best of the board of directors. I don't know, but I'm awfully frustrated (and thankful at the same time). AMPE has done pretty well. My first major public purchase was of almost 40,000 share at over $7 in 2011. (I bought a lot shares many, many years before that - well before the company was public and way before Macaluso was on the scene.) I am awfully thankful that the stock is back up there again two years later. But so much progress has been made and the company has totally (we'll... not totally, but certainly) failed to get the market to realize it and to have it reflected in its market value.
ed007... again... you are right. Totally unfair to lay it all at the feet on an independent director. I started there just for the heck of it. What's up? What's up is that I am just really frustrated. ... Believe me, I'm thankful and appreciative, but still frustrated.
Agnew!!! You're hurting my feelings. I'm on your side. Just trying to get movement towards what we all want. You have no idea how dedicated i am to AMPE. And you'r right... at these prices i don't have $1M in AMPE stock. It is slightly under that (wasn't a few weeks ago).
dko... I agree with the first part of your post. Mike has done an awesome job.
Maybe my "used car salesman" was a bit harsh. However, I do believe his highly promotional nature - great it making something out of nothing, or for taking something off the radar into the mainstream (which he has done with AMPE) - may not be the best to bring the company to the promised land.
I also agree that if every time the stock goes down we blame the CEO, then we are foolish. I think its more about the stock not going up - or being ANYWHERE near where it should be - at ANY time, EVER. Things (especially stocks) will go up and down. There will be advances and set-backs, good and bad. Not all of it (or even some of it) is the CEO's fault. But to NEVER have the company EVER come ANYWHERE near what should be its market value, is a HUGE flaw. To be discounted some by the market - hey, it happens. To suffer a loss of value. To have ups and downs... it all happens. But to have one of the top football teams on earth, but to not apply to play in the NFL, or in front a national audience, is just foolish.
Again... you are right... Macaluso has been truly awesome and done what few others could possibly have done. I myself took a small company from nothing to $250M in no time. Went public. And made the same mistakes that AMPE is making now. I was one of the only people who could have done what I did. But I was the wrong guy to move it beyond that. Maybe the same holds true here... or else I'm just projecting my personal failure onto someone else.
You guys are both right. I will side a little more on Ed's side simply because the company barely had 15 minutes to speak and needed to get to the selling points that mattered to the perspective buyers. Those perspective buyers that were present probably didn't need to be educated on FDA timelines or designations and probably needed to hear more about how Ampion is better than current remedies and the potential an approved Ampion has in the marketplace. Just my $.02
The guy is evidently a heavy, but even if not, raw intelligence and common sense can often trump sophistication.
I went to a school that supposedly pulled from the top 5% of the nation (probably top 1% now) and some of the statements made publically in small lecture halls made me wonder how stupid the other 95% were....but if from the right prep school with reviewed SAT's you can get in regardless of intellect....an interesting world in which we reside....and soon to be far more interesting...
Certainly yet another one of those days I don't want to look at my account. Part of it may just be due to being tied to index funds. Maybe automated trading accounts for another part. So long as the smart money keeps accumulating, the data remains positive, it's hard to see anything wrong with the 6-12 month timeframe. The problem in this drug development game is that the potential for disappointment is high, even with the best of science.
Repurposed drugs is a MAJOR trend, fully supported by NIH and FDA. The fact that many investors don't yet understand the advantage of taking safe compounds into new indications is true. But they will get educated eventually.
That's because you still live in the toilet and you only know and speak what your are full of.
Sentiment: Strong Buy